PharmiWebOpinion

MMJ International Holdings Rejects "Anti-Marijuana" Label, Defends Science Based Standards for Cannabinoid Medicines

Clinical-Stage Pharmaceutical Developer Says Recent Coverage Misses the Real Story: Marijuana Chemistry, Safety, and ...
Opinion
PharmiWebOpinion

Congress Banned It. Europe Rejected It. CMS Is Still Giving CBD to Seniors

Medicare's Hemp Program Continues Despite Federal Restrictions Taking Effect in Less Than Six MonthsCourt Declines to Address Safety, Legality, or Congressional Intent, Allowing CMS Hemp Program to ...
PharmiWeb

PharmaEssentia to Present New Clinical Data Supporting the Use of Ropeginterferon Alfa-2b in Essential Thrombocythemia at ASCO and EHA 2026

Two-year and post-hoc SURPASS-ET analyses highlight the impact of treatment timing, with durable responses and improved progression-free survival supporting consideration of earlier ropeginterferon ...
PharmiWeb

L&T Technology Services Unveils Europe’s First EI Center; Ushers in New Era of Engineering Intelligence for Products, Platforms & Manufacturing

New EI CoE in Munich to serve LTTS’ clients in Mobility, Sustainability & Tech segments, accelerating applied AI adoption and ...
PharmiWeb

BioInvent Reveals Solid Data with its TNFR2 Antibody BI-1808 and KEYTRUDA(R) (pembrolizumab) in Advanced Ovarian Cancer at ASCO

BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...
PharmiWeb

Medicure Announces AGM Results and Appointment of New Director

WINNIPEG, MB / ACCESS Newswire / May 21, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and ...
PharmiWeb

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 2026

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for ...
PharmiWeb

Securities Fraud Investigation Into Phreesia Inc. (PHR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud ...

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Phreesia Inc. (“Phreesia” or the “Company”) (NYSE ...
PharmiWeb

Study confirms use of Pepaxti in a broader population, with strong data in the 50% of RRMM patients that suffer from reduced kidney function

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the publication of the results from the Phase 2 BRIDGE (OP-107) clinical study ...
PharmiWeb

Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver ...

Webcast with Hepatitis B experts to discuss new biopsy and clinical data from the ongoing ELIMINATE-B trial in chronic hepatitis B -- Webcast will be held May 27th, 2026, at 8:00 AM EDT -DURHAM, N.C.- ...
PharmiWeb

858 Therapeutics Announces Initial Data from First-in-Human Phase 1/2 Trial of PARG Inhibitor ETX-19477 to be Presented at 2026 ASCO Annual Meeting

ETX-19477 demonstrated robust efficacy, with a 57% objective response rate in BRCA-mutated platinum-resistant ovarian cancer and earlier-line HR+/HER2- breast cancer (n=7) ---- Favorable safety ...
PharmiWeb

Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline

Late-breaking Phase 3 SUCCESSOR-2 study results highlight potential of mezigdomide, a novel CELMoD from the Company’s targeted protein degradation platform, in relapsed or refractory multiple ...